FLT3 and acute myeloid leukemia: Despite some progress than before, outcomes in high‐risk AML‐M5 children with only conventional chemotherapy remain unsatisfactory, and HSCT may be with a beneficial effect in FLT3‐ITD carriers, age ≤ 3 years old, and hyperleukocytic patients.